Post-Approved Phase III Study of 1-LV/5FU Therapy
Post-Approved Phase III Study of 1-LV/5FU Therapy
The purpose of the study is to verify non-inferiority of survival time between Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable advanced or recurrent gastric cancer. Secondary endpoints include response rates, duration of responses, time to progression (TTP) safety and quality of life (QOL).
Inclusion Criteria:
Other inclusion applies
Exclusion Criteria:
Other exclusion applies
Fukuroi-shi, 437-0061, Japan
Funai-gun, 629-0392, Japan
Ichihara-shi, 290-0003, Japan
Kisaradu-shi, 292-8535, Japan
Kitaadachi-gun, 362-0806, Japan
Koto-ku, Tokyo, 135-8577, Japan
Misawa-shi, 033-0001, Japan
Sagamiharashi, 228-8520, Japan
Sapparo City, 064-0923, Japan
Sasebo-shi, 857-8511, Japan
Sizuoka-shi, 420-8623, Japan
Takatuki-si, 569-8666, Japan
Tsuchiura-shi, 300-0053, Japan
Uji-shi, 611-0042, Japan